Related Experiment Video
Updated: Mar 16, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Fabry Disease: A Disorder of Childhood Onset
Raphael Schiffmann1, Markus Ries2
1Institute of Metabolic Disease, Baylor Research Institute, Dallas, Texas.
Insights
Fabry disease, a genetic disorder, increases risks for vasculopathy and organ damage. Early diagnosis and treatment are crucial, but overdiagnosis must be avoided.
Area of Science:
- Genetics
- Metabolic Disorders
- Neurology
Background:
- Fabry disease is an X-linked disorder of glycosphingolipids.
- It elevates the risk of systemic vasculopathy, ischemic stroke, neuropathy, cardiac dysfunction, and kidney disease.
- Caused by GLA gene variants, its incidence may be underestimated.
Purpose of the Study:
- To review the clinical manifestations and management of Fabry disease.
- To highlight the challenges in diagnosis, including under- and overdiagnosis.
- To discuss current and emerging therapeutic strategies.
Main Methods:
- Extensive PubMed search on Fabry disease.
- Analysis based on cumulative clinical experience.
Main Results:
- Complications are often nonspecific and mimic common disorders.
- Some GLA gene variants are benign, necessitating caution against overdiagnosis and unjustified enzyme replacement therapy.
- Current specific therapies show modest clinical effects, with novel agents under development.
Conclusions:
- Fabry disease is a treatable genetic risk factor for various organ complications.
- The condition may be frequently overlooked or occasionally overdiagnosed.
- Standard therapies are essential for managing organ damage and slowing disease progression.
Background:
Fabry disease, an X-linked disorder of glycosphingolipids, markedly increases the risk of systemic vasculopathy, ischemic stroke, small-fiber peripheral neuropathy, cardiac dysfunction, and chronic kidney disease.
Methods:
We performed an extensive PubMed search on the topic of Fabry disease and drew from our cumulative 43 years of experience.
Results:
Most of these complications are nonspecific in nature and clinically indistinguishable from similar abnormalities that occur in the context of more common disorders in the general population. This disease is caused by variants of the GLA gene, and its incidence may have been underestimated. However, one must also guard against overdiagnosis of Fabry disease and unjustified enzyme replacement therapy, because some of the gene variants are benign. Specific therapy for Fabry disease has been developed in the last few years, but its clinical effect has been modest. Novel therapeutic agents are being developed. Standard "nonspecific" medical and surgical therapy is necessary and effective in slowing deterioration or compensating for organ failure in patients with Fabry disease.
Conclusions:
Fabry disease is a treatable and modifiable genetic risk factor for a myriad of clinical organ complications. Fabry disease may be frequently overlooked but on occasion overdiagnosed.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Inborn Errors of Metabolism
Lysosomal Hydrolases
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...

